Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination With LY3202626 in Early Symptomatic Alzheimer's Disease

Trial Profile

Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination With LY3202626 in Early Symptomatic Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs LY 3002813 (Primary) ; LY 3202626 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 22 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 11 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top